Overview

Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will hope to show that the treatment of the patient's perennial allergic rhinitis (PAR) using Nasonex® (mometasone furoate nasal spray) will result in improvement of the nasal symptoms of PAR and of nighttime sleep-disordered breathing, thereby resulting in improved sleep quality, less daytime sleepiness, improved daytime functioning, and improved quality of life.
Phase:
Phase 4
Details
Lead Sponsor:
Schering-Plough
Treatments:
Mometasone Furoate